Compounds > nefiracetam
Page last updated: 2024-09-23

nefiracetam

Cross-References

ID SourceID
PubMed CID71157
CHEMBL ID260829
CHEBI ID135004
SCHEMBL ID135856
MeSH IDM0164013

Synonyms (89)

Synonym
AC-15655
AB01274721-01
motiva
dm-9384
nefiracetam ,
dzl-221
translon
77191-36-7
n-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
dm 9384
n-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineacetamide
ccris 6729
brn 6848330
nefiracetam [inn]
2-oxo-1-pyrrolidineaceto-2',6'-xylidide
n-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide
1-pyrrolidineacetamide, n-(2,6-dimethylphenyl)-2-oxo-
dmppa
nefiracetamum [inn-latin]
CHEBI:135004
NCGC00186006-01
nsc-759830
CHEMBL260829
A838998
NCGC00186006-02
HMS3261I16
1jk12gx30n ,
nsc 759830
nefiracetamum
unii-1jk12gx30n
tox21_303025
cas-77191-36-7
dtxcid20923
NCGC00256487-01
dtxsid2020923 ,
tox21_113521
tox21_201916
NCGC00259465-01
nsc759830
pharmakon1600-01502315
smr001456240
MLS004774126
FT-0630853
NCGC00186006-04
LP00447
AB04796
S1969
AKOS015895083
nefiracetam [jan]
nefiracetam [mi]
nefiracetam [mart.]
CCG-213818
HY-B0340
MLS006010195
SCHEMBL135856
NCGC00186006-03
tox21_113521_1
KS-5226
NCGC00261132-01
tox21_500447
NGHTXZCKLWZPGK-UHFFFAOYSA-N
n-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl]acetamide
AC-32883
N0996
AB01274721_03
AB01274721_02
mfcd00209882
dm9384
SR-01000883754-1
sr-01000883754
HMS3655N05
nefiracetam, solid
Z79686019
SW219212-1
DB13082
dm-9384; dzl-221; dm9384; dzl221; dm 9384; dzl 221
BCP21371
Q6039388
cas#77191-36-7
nefiracetam (translon)
dm9384;dzl-221
SDCCGSBI-0633714.P001
NCGC00186006-11
HMS3884C18
T72927
dzl 221
CDA19136
EN300-54992
SY052956

Research Excerpts

Overview

ExcerptReference
"Nefiracetam is a novel pyrrolidone-type nootropic compound shown in preliminary trials to increase blood flow and improve patient outlook and energy following stroke. "( Clarence-Smith, K; Jorge, RE; Robinson, RG; Starkstein, S, 2009)
"Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect."( Moriguchi, S, 2011)
"Nefiracetam is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and post-stroke vascular-type dementia. "( Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003)
"Nefiracetam (NEF) is a novel pyrrolidone-type nootropic agent, and it has been reported to possess various pharmacologic effects as well as cognition-enhancing effects. "( Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A, 2005)
"Nefiracetam is a novel pyrrolidone-type nootropic agent, and it has been reported to possess a potential for antiepileptic therapy as well as cognition-enhancing effects. "( Aoki, T; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Satoh, H; Takasuna, K; Takazawa, A; Yamauchi, T, 2005)
"Nefiracetam (NEF) is a novel pyrrolidonetype nootropic agent, and it has been reported to possess various pharmacologic effects as well as cognition-enhancing effects. "( Kasai, Y; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A; Yamauchi, T; Yamazaki, O, 2005)
"Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. "( Fukunaga, K; Han, F; Moriguchi, S; Narahashi, T; Shioda, N, 2008)
"Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits. "( Doyle, E; O'Boyle, KM; Regan, CM; Shiotani, T, 1996)
"Nefiracetam (DM-9384) is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and poststroke vascular-type dementia. "( Kuryatov, A; Lindstrom, JM; Narahashi, T; Yeh, JZ; Zhao, X, 2001)
"Nefiracetam is a new pyrrolidone nootropic drug that is being developed for clinical use in the treatment of post-stroke vascular-type and Alzheimer's-type dementia. "( Narahashi, T; Yeh, JZ; Zhao, X, 2001)
"Nefiracetam (DM-9384) is a cerebral metabolic product under development by Daiichi for the potential treatment of the after-effects of cerebrovascular disorders. "( Crespi, F, 2002)

Effects

ExcerptReference
"Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM."( Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004)
"Nefiracetam has been reported to increase intracellular cyclic AMP levels and enhance calcium channel current. "( Mizuno, T; Nabeshima, T; Nitta, A; Yamada, K; Yan, Y, 2004)

Treatment

ExcerptReference
"Nefiracetam treatment (1 mg/kg/day) significantly elevated CaMKII but not ERK activities in the amygdala, prefrontal cortex and hippocampal CA1 regions."( Fukunaga, K; Han, F; Lu, YM; Nakano, T; Shioda, N; Yamamoto, Y, 2009)
"Nefiracetam treatment restored LTP-induced PKCalpha (Ser657) and NR1 (Ser896) phosphorylation as well as increase in their basal phosphorylation in the hippocampal CA1 region of OBX mice."( Fukunaga, K; Han, F; Moriguchi, S; Nakagawasai, O; Nakajima, T; Narahashi, T; Shioda, N; Tadano, T; Yamamoto, Y; Yeh, JZ, 2009)
"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve."( Moriguchi, S, 2011)
"The nefiracetam-treated ME rat showed a shortened escape latency in the retention test on day 17 as well as in the contraposition test on day 18."( Ando, T; Fukatsu, T; Miyake-Takagi, K; Nagakura, A; Niimura, M; Takagi, N; Takeo, S; Tanonaka, K, 2003)
"Nefiracetam treatment did not affect the PKA activity."( Fukunaga, K; Maejima, H; Marszalec, W; Moriguchi, S; Narahashi, T; Shioda, N; Yeh, JZ; Zhao, X, 2007)
"Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner."( Fukunaga, K; Han, F; Moriguchi, S; Narahashi, T; Shioda, N, 2008)
"Treatment with nefiracetam did not prove to be more efficacious than placebo in ameliorating apathy in stroke. "( Almeida, OP; Brockman, S; Bruce, DG; Davis, WA; Hatch, KK; Robinson, RG; Starkstein, SE, 2016)
"Treatment with nefiracetam reduced the prolongation of the escape latency in the water maze test on days 7-9 after microsphere embolism-induced sustained cerebral ischemia, suggesting an improvement in the spatial learning function."( Ando, T; Kago, T; Takagi, K; Takagi, N; Takeo, S, 2005)
"Pretreatment with nefiracetam reversed the inhibitory effects of chlordiazepoxide and apomorphine, but not those of methamphetamine, on latent learning."( Hasegawa, T; Ichihara, K; Nabeshima, T; Nakayama, S; Shiotani, T; Yamada, K, 1994)
"Treatment with nefiracetam (10 mg/kg, p.o.) produced a significant increase in the level of ACh in the brain dialysate, compared with the vehicle-treated group."( Kato, T; Mori, K; Nabeshima, T; Sakurai, T; Takano, E; Watabe, S, 1998)

Drug Classes (2)

ClassDescription
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency40.99990.000714.592883.7951AID1259369; AID1259392
EWS/FLI fusion proteinHomo sapiens (human)Potency2.95660.001310.157742.8575AID1259256
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency9.771219.739145.978464.9432AID1159509
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency0.75690.425612.059128.1838AID504536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID322668Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 30 ug/kg, icv after 45 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID322667Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 30 ug/kg, icv after 30 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID322669Antihyperalgesic activity in Sprague-Dawley rat assessed as lesioned paw pressure threshold at 30 ug/kg, icv after 60 mins2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (141)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.42)18.7374
1990's57 (40.43)18.2507
2000's57 (40.43)29.6817
2010's16 (11.35)24.3611
2020's9 (6.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.08%)5.53%
Reviews8 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other133 (92.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nefiracetam Therapy of Alzheimer's Type Dementia[NCT00001933]Phase 250 participants Interventional1999-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
gabapentin[no description available]medium10gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
dimiracetam[no description available]medium10
levetiracetam[no description available]medium30pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
cuminaldehyde[no description available]medium10benzaldehydesinsecticide;
plant metabolite;
volatile oil component
vanillin[no description available]medium10benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
phenytoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
aniracetam[no description available]medium100N-acylpyrrolidine;
pyrrolidin-2-ones
antipyrine[no description available]medium10pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
bendiocarb[no description available]medium10benzodioxoles;
carbamate ester		agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
buspirone[no description available]medium10azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
carbofuran[no description available]medium101-benzofurans;
carbamate ester		acaricide;
agrochemical;
avicide;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nematicide
carisoprodol[no description available]medium10carbamate estermuscle relaxant
chlorpropham[no description available]medium10benzenes;
carbamate ester;
monochlorobenzenes		herbicide;
plant growth retardant
chlorzoxazone[no description available]medium101,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cinoxacin[no description available]medium10cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
clonidine[no description available]medium10clonidine;
imidazoline
droperidol[no description available]medium10aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
etazolate[no description available]medium10ethyl ester;
hydrazone;
pyrazolopyridine		alpha-secretase activator;
antidepressant;
antipsychotic agent;
anxiolytic drug;
GABA agent;
neuroprotective agent;
phosphodiesterase IV inhibitor
fenbendazole[no description available]medium10aryl sulfide;
benzimidazoles;
carbamate ester		antinematodal drug
fenofibrate[no description available]medium10aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenspiride[no description available]medium10azaspiro compound
glafenine[no description available]medium10aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
glipizide[no description available]medium10aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
ibudilast[no description available]medium10pyrazolopyridine
idebenone[no description available]medium201,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
beta-lapachone[no description available]medium10benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
leflunomide[no description available]medium10(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
meprobamate[no description available]medium10organic molecular entity
modafinil[no description available]medium10monocarboxylic acid amide;
sulfoxide
oxibendazole[no description available]medium10benzimidazoles;
carbamate ester
phenprobamate[no description available]medium10benzenes
propentofylline[no description available]medium10oxopurine
propoxur[no description available]medium10aromatic ether;
carbamate ester		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
sb 206553[no description available]medium10pyrroloindole
streptonigrin[no description available]medium10pyridines;
quinolone		antimicrobial agent;
antineoplastic agent
thalidomide[no description available]medium10phthalimides;
piperidones
tizanidine[no description available]medium10benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
todralazine[no description available]medium10phthalazines
tolperisone[no description available]medium10aromatic ketone
trazodone[no description available]medium10monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
delavirdine[no description available]medium10aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zonisamide[no description available]medium101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
zopiclone[no description available]medium10monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride[no description available]medium10
physostigmine[no description available]medium40carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
salicylaldehyde[no description available]medium10hydroxybenzaldehydenematicide;
plant metabolite
2,4-dihydroxybenzaldehyde[no description available]medium10dihydroxybenzaldehyde
triclocarban[no description available]medium10dichlorobenzene;
monochlorobenzenes;
phenylureas		antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
heptanal[no description available]medium10medium-chain fatty aldehyde;
n-alkanal;
saturated fatty aldehyde		biomarker
neostigmine bromide[no description available]medium10bromide salt
nicarbazin[no description available]medium10organic molecular entity
diperodon[no description available]medium10carbamate ester
metaxalone[no description available]medium10aromatic ether
aminocarb[no description available]medium10carbamate ester;
toluenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
molluscicide
methiocarb[no description available]medium10aryl sulfide;
carbamate ester;
methyl sulfide		acaricide;
agrochemical;
avicide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
environmental contaminant;
insecticide;
molluscicide;
xenobiotic
perillaldehyde[no description available]medium10aldehyde;
olefinic compound		human metabolite;
mouse metabolite;
volatile oil component
promecarb[no description available]medium10alkylbenzene
propham[no description available]medium10benzenes;
carbamate ester		herbicide;
plant growth retardant
phenmedipham[no description available]medium10carbamate esterenvironmental contaminant;
herbicide;
xenobiotic
metergoline[no description available]medium10carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
benomyl[no description available]medium10aromatic amide;
benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		acaricide;
anthelminthic drug;
antifungal agrochemical;
microtubule-destabilising agent;
tubulin modulator
oxadiazon[no description available]medium10aromatic ether
toloxatone[no description available]medium10oxazolidinone;
primary alcohol;
toluenes
vinclozolin[no description available]medium10dicarboximide;
dichlorobenzene;
olefinic compound;
oxazolidinone
thidiazuron[no description available]medium10ureas
oxfendazole[no description available]medium10benzimidazoles;
carbamate ester;
sulfoxide		antinematodal drug
talniflumate[no description available]medium10benzofurans
fenoxycarb[no description available]medium10aromatic ether;
carbamate ester		environmental contaminant;
insecticide;
juvenile hormone mimic;
xenobiotic
flupirtine[no description available]medium10aminopyridine
remoxipride[no description available]medium10dimethoxybenzene
clomazone[no description available]medium10isoxazolidinone;
monochlorobenzenes		agrochemical;
carotenoid biosynthesis inhibitor;
environmental contaminant;
herbicide;
xenobiotic
sertindole[no description available]medium10heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
ziprasidone[no description available]medium101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zolmitriptan[no description available]medium10oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
capecitabine[no description available]medium10carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
befuraline[no description available]medium10
amperozide[no description available]medium10diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
citronellal, (r)-isomer[no description available]medium10citronellal
phenserine[no description available]medium10
linezolid[no description available]medium10acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
citral[no description available]medium10enal;
monoterpenoid;
polyprenal		plant metabolite;
volatile oil component
2-amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophene[no description available]medium10
thiophanate[no description available]medium10benzimidazole precursor fungicide;
carbamate ester;
carbamate fungicide;
thioureas		antifungal agrochemical
sb 242084[no description available]medium10
chrysin[no description available]medium107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
2-nonenal, (trans)-isomer[no description available]medium10enal;
medium-chain fatty aldehyde;
monounsaturated fatty aldehyde		plant metabolite
dantrolene[no description available]medium10
psn 632408[no description available]medium10
febantel[no description available]medium10aryl sulfide
fenobam[no description available]medium10ureas
mifepristone[no description available]medium103-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
quinuclidines[no description available]medium10quinuclidines;
saturated organic heterobicyclic parent
veratridine[no description available]medium10
n-methylaspartate[no description available]medium40amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
galantamine[no description available]medium20benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
1-aminoindan-1,5-dicarboxylic acid[no description available]medium10
piracetam[no description available]medium40organonitrogen compound;
organooxygen compound
kainic acid[no description available]medium40dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
gamma-aminobutyric acid[no description available]medium70amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
cytochalasin b[no description available]medium10cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
colforsin daropate[no description available]medium10acetate ester;
carboxylic ester;
cyclic ketone;
diol;
organic heterotricyclic compound;
tertiary amino compound		adenylate cyclase agonist;
antihypertensive agent;
cardiotonic drug;
vasodilator agent
colforsin[no description available]medium10acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
kynurenic acid[no description available]medium10monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
glycine[no description available]medium20alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
7-chlorokynurenic acid[no description available]medium10organochlorine compound;
quinolinemonocarboxylic acid		neuroprotective agent;
NMDA receptor antagonist
dihydro-beta-erythroidine[no description available]medium10delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound		nicotinic antagonist
methyllycaconitine[no description available]medium10
mecamylamine[no description available]medium40primary aliphatic amine
aconitine[no description available]medium10
hexamethonium[no description available]medium10quaternary ammonium salt
piperidines[no description available]medium10
donepezil[no description available]medium10aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
ro 5-4864[no description available]medium20
methamphetamine[no description available]medium40amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
scopolamine hydrobromide[no description available]medium120
selegiline[no description available]medium10selegiline;
terminal acetylenic compound		geroprotector
tacrine[no description available]medium30acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
nnc 711[no description available]medium10
ibuprofen[no description available]medium10monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
rolipram[no description available]medium20pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
morphine[no description available]medium30morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
hydroxyindoleacetic acid[no description available]medium30indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
3,4-dihydroxyphenylacetic acid[no description available]medium40catechols;
dihydroxyphenylacetic acid		human metabolite
homovanillic acid[no description available]medium40guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
tetrodotoxin[no description available]medium10azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
glutamic acid[no description available]medium20glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
ethylcholine aziridinium[no description available]medium10
choline[no description available]medium10cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
phosphatidylcholines[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine
framycetin[no description available]medium10aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
pentobarbital[no description available]medium10barbituratesGABAA receptor agonist
codeine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
ovalbumin[no description available]medium10
apomorphine[no description available]medium30aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
chlordiazepoxide[no description available]medium20benzodiazepine
bucladesine[no description available]medium103',5'-cyclic purine nucleotide
nadp[no description available]medium10
propofol[no description available]medium10phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
pyrroles[no description available]medium10pyrrole;
secondary amine
kt 5720[no description available]medium10carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
ucn 1028 c[no description available]medium10
2-amino-5-phosphonovalerate[no description available]medium10non-proteinogenic alpha-amino acidNMDA receptor antagonist
bisindolylmaleimide i[no description available]medium20
bicuculline[no description available]medium30benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
h 89[no description available]medium10N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
8-hydroxy-2-(di-n-propylamino)tetralin[no description available]medium10phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
4-iodo-2,5-dimethoxyphenylisopropylamine[no description available]medium10amphetamines;
dimethoxybenzene;
organoiodine compound
glutamine[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
enprofylline[no description available]medium10oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
theophylline[no description available]medium10dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
naloxone[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
adenosine diphosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
phosphocreatine[no description available]medium10phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite
verapamil[no description available]medium10aromatic ether;
nitrile;
polyether;
tertiary amino compound
methoxyhydroxyphenylglycol[no description available]medium10methoxybenzenes;
phenols
carbon monoxide[no description available]medium10carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
cycloheximide[no description available]medium20antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
oxiracetam[no description available]medium20organonitrogen compound;
organooxygen compound
indeloxazine[no description available]medium20indene
pantothenic acid[no description available]medium10pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
ubiquinone[no description available]medium10
pantogab[no description available]medium10
flumazenil[no description available]medium10ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
picrotoxin[no description available]medium10
muscimol[no description available]medium10alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
2-carboxyethyl gamma-aminobutyric acid[no description available]low00organonitrogen compound;
organooxygen compound
carcinine[no description available]low00beta-alanine derivative;
imidazoles;
monocarboxylic acid amide;
organonitrogen compound;
organooxygen compound		antioxidant;
crustacean metabolite
dimethyl pyrocarbonate[no description available]low00organooxygen compound
methoxyamine[no description available]low00organooxygen compound
nialamide[no description available]low00organonitrogen compound;
organooxygen compound
etozolin[no description available]low00organonitrogen compound;
organooxygen compound
2-acetyltributylcitrate[no description available]low00organooxygen compound
guanidine carboxamide[no description available]low00organooxygen compound
cuprizone[no description available]low00organonitrogen compound;
organooxygen compound
cdta[no description available]low00organooxygen compound
alpha-fluoro-beta-alanine[no description available]low00organonitrogen compound;
organooxygen compound
ammonium bicarbonate[no description available]low00organooxygen compound
4-amino-3-phenylbutyric acid[no description available]low00organonitrogen compound;
organooxygen compound
zinc carbonate[no description available]low00organooxygen compound
nicofuranose[no description available]low00organooxygen compound
lodoxamide[no description available]low00organonitrogen compound;
organooxygen compound
Arbaclofen[no description available]low00organonitrogen compound;
organooxygen compound
pramiracetam[no description available]low00organonitrogen compound;
organooxygen compound
etiracetam[no description available]low00organooxygen compound
azidoamphenicol[no description available]low00organonitrogen compound;
organooxygen compound
telmesteine[no description available]low00organonitrogen compound;
organooxygen compound
pivagabine[no description available]low00organonitrogen compound;
organooxygen compound
betamipron[no description available]low00organonitrogen compound;
organooxygen compound
2-carboxythiazolidine-4-carboxylic acid[no description available]low00organonitrogen compound;
organooxygen compound
alpha-lapachone[no description available]low00organic heterotricyclic compound;
organooxygen compound
5,5-dimethylthiazolidine-4-carboxylic acid[no description available]low00organonitrogen compound;
organooxygen compound
aurofusarin[no description available]low00organic heterotricyclic compound;
organooxygen compound
7,9-dimethyl-9aH-quinolizine-1,2,3,4-tetracarboxylic acid tetramethyl ester[no description available]low00organooxygen compound
n-nitrosothiazolidine-4-carboxylic acid[no description available]low00organonitrogen compound;
organooxygen compound
pyridinoline[no description available]low00organonitrogen compound;
organooxygen compound
4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide[no description available]low00organonitrogen compound;
organooxygen compound
paspaline[no description available]low00organic heterotricyclic compound;
organooxygen compound
2-methyl-5-nitroimidazol-1-ylacetic acid[no description available]low00organonitrogen compound;
organooxygen compound
3-carboxymethyl-6-benzyl-2,5-diketopiperazine[no description available]low00organonitrogen compound;
organooxygen compound
3,5-diiodothyronine[no description available]low00organonitrogen compound;
organooxygen compound
8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline[no description available]low00organonitrogen compound;
organooxygen compound
salvinorin a[no description available]low00organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
merodantoin[no description available]low00organonitrogen compound;
organooxygen compound
sch 45752[no description available]low00organic heterotricyclic compound;
organooxygen compound
argininic acid[no description available]low00organonitrogen compound;
organooxygen compound
delta-guanidinovaleric acid[no description available]low00organonitrogen compound;
organooxygen compound
chlorocarbonic acid[no description available]low00organooxygen compound
byssochlamic acid[no description available]low00organooxygen compound
mirestrol[no description available]low00organic heterotricyclic compound;
organooxygen compound
isoputreanine[no description available]low00organonitrogen compound;
organooxygen compound
cyclo(glycylprolyl)[no description available]low00organonitrogen compound;
organooxygen compound
cyclo(tyrosyl-prolyl)[no description available]low00organonitrogen compound;
organooxygen compound
columbin[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-cyclopropyl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-1-thiophen-2-ylethyl]-4-thiadiazolecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(cyclopentylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-4-thiadiazolecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(cyclohexylamino)-1-(2-furanyl)-2-oxoethyl]-N-(2-furanylmethyl)-2-furancarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(thiophen-2-ylmethyl)amino]-2-(2-furanyl)-N-(3-methylbutyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-butan-2-yl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-4-thiadiazolecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N'-[2-(cyclohexylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylpentanediamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(5-chloro-2-methoxyanilino)-2-oxoethyl]-N-cyclohexyl-2-furancarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methoxyanilino)-N-(2-methylbutan-2-yl)-2-(1-methyl-2-pyrrolyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methylanilino)-N-(2-furanylmethyl)-2-(3-pyridinyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(tert-butylamino)-2-oxo-1-pyridin-4-ylethyl]-N-cyclopropyl-4-thiadiazolecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-cyclopentyl-2-[2-oxolanylmethyl-(1-oxo-2-thiophen-2-ylethyl)amino]-2-thiophen-2-ylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
N'-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N'-(3-fluorophenyl)-N-(3-pyridinyl)butanediamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-tert-butyl-2-(2-furanyl)-2-[[2-[5-(5-methyl-2-furanyl)-2-tetrazolyl]-1-oxoethyl]-(thiophen-2-ylmethyl)amino]acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N'-[1-[(cyclohexylamino)-oxomethyl]cyclopentyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylbutanediamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-propan-2-ylamino]-2-(2,5-dimethoxyphenyl)-N-(2-furanylmethyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(2-furanylmethyl)amino]-N-cyclohexyl-2-(2-fluorophenyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N'-[2-(cyclopentylamino)-2-oxoethyl]-N'-(3,4-dimethylphenyl)-N-(2-pyridinyl)pentanediamide[no description available]low00organonitrogen compound;
organooxygen compound
N-(1,3-benzodioxol-5-yl)-N-[1-(4-chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl]-2-pyrazinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[(3-methyl-2,4-dioxo-5-thiazolidinyl)amino]benzoic acid[no description available]low00organonitrogen compound;
organooxygen compound
4-amino-N5-[2-(2-methoxyethylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N5-(thiophen-2-ylmethyl)isothiazole-3,5-dicarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N'-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylbutanediamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[1,3-benzodioxol-5-yl-[2-(1-benzotriazolyl)-1-oxoethyl]amino]-N-(2-methoxyethyl)-2-thiophen-2-ylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
1-[2-[cyano-(4,6-dimethyl-2-pyrimidinyl)amino]-1-oxoethyl]-4-piperidinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
4-[3-(4-methoxyanilino)-3-oxopropyl]-1-piperazinecarboxylic acid ethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
3-[[(5-bromo-3-pyridinyl)-oxomethyl]amino]propanoic acid[no description available]low00organonitrogen compound;
organooxygen compound
N-(2,4-dimethoxyphenyl)-3-(4-morpholinyl)propanamide[no description available]low00organonitrogen compound;
organooxygen compound
1-[[2-(3-methylanilino)-1-oxoethyl]amino]-3-phenylthiourea[no description available]low00organonitrogen compound;
organooxygen compound
2-oxo-3-benzo[h][1]benzopyrancarboxylic acid ethyl ester[no description available]low00organic heterotricyclic compound;
organooxygen compound
1-(2,3-dimethyl-1-indolyl)-2-(4-methyl-1-piperidinyl)ethanone[no description available]low00organonitrogen compound;
organooxygen compound
1-(N-[2-(Benzotriazol-1-yl)acetyl]-4-methoxyanilino)-N-cyclopentylcyclohexane-1-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound		anticoronaviral agent
4-(4-methylphenyl)-2-[[3-(4-morpholinyl)-1-oxopropyl]amino]-3-thiophenecarboxylic acid ethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
3-imino-2-benzo[f][1]benzopyrancarbothioamide[no description available]low00organic heterotricyclic compound;
organooxygen compound
3-(3-oxo-2-benzo[f][1]benzopyranyl)-1-phenyl-4-pyrazolecarboxaldehyde[no description available]low00organic heterotricyclic compound;
organooxygen compound
2-[(4-fluorophenyl)hydrazo]-2-oxoacetic acid ethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
4-[(3,5-dimethylphenyl)-oxomethyl]-1,3-dihydroquinoxalin-2-one[no description available]low00organonitrogen compound;
organooxygen compound
N-(3,5-dimethoxyphenyl)-2-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
5-[(2-chlorophenyl)hydrazo]-3,3-bis(hydroxymethyl)-2H-1,4-oxazin-6-one[no description available]low00organonitrogen compound;
organooxygen compound
2-[(3-acetyl-5-oxo-4H-imidazol-2-yl)thio]-N-(4-methyl-5-phenyl-2-thiazolyl)-N-prop-2-enylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[(3-acetyl-5-oxo-4H-imidazol-2-yl)thio]-N-(4,5-diphenyl-2-thiazolyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-chloro-N-[3-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-3-oxopropyl]benzamide[no description available]low00organonitrogen compound;
organooxygen compound
4-bromo-N-[3-oxo-3-(2-thiazolylamino)propyl]benzamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[3-[4-[(2-methoxyphenyl)sulfamoyl]anilino]-3-oxopropyl]-2-furancarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
3-(4-Chloroanilino)propanoic acid[no description available]low00organonitrogen compound;
organooxygen compound
1,4-dihydroxy-4a,5,6,7,8,8a-hexahydroquinoxaline-2,3-dione[no description available]low00organonitrogen compound;
organooxygen compound
2-(2-furanyl)-4-thiazolidinecarboxylic acid[no description available]low00organonitrogen compound;
organooxygen compound
methyl-thiohydantoin-tryptophan[no description available]low00organonitrogen compound;
organooxygen compound
2-(difluoromethyl)-4-benzo[h][1]benzopyranone[no description available]low00organic heterotricyclic compound;
organooxygen compound
3-hydroxy-7-methyl-3-(4-morpholinyl)-5-nitro-1H-indol-2-one[no description available]low00organonitrogen compound;
organooxygen compound
5-bromo-3-hydroxy-3-(4-methyl-1-piperidinyl)-1H-indol-2-one[no description available]low00organonitrogen compound;
organooxygen compound
N-(3,4-dimethylphenyl)-2-(4-methylanilino)-6-oxo-4,5-dihydro-1H-pyrimidine-4-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-(3-chloro-4-methylphenyl)-4-oxo-3,10-dihydro-2H-pyrimido[1,2-a]benzimidazole-2-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(1-azepanyl)-2-oxoethyl]-N-[(4-chlorophenyl)methyl]methanesulfonamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[1-[[[(3-chloro-1-benzothiophen-2-yl)-oxomethyl]amino]-sulfanylidenemethyl]-3-oxo-2-piperazinyl]acetic acid methyl ester[no description available]low00organonitrogen compound;
organooxygen compound
2-(2-methoxy-2-oxoethyl)-3-oxo-1-piperazinecarboxylic acid tert-butyl ester[no description available]low00organonitrogen compound;
organooxygen compound
albutoin[no description available]low00organonitrogen compound;
organooxygen compound
2-thioxo-4-thiazolidinecarboxylic acid[no description available]low00organonitrogen compound;
organooxygen compound
momilactone b[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-[[2-(4-chlorophenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]benzenesulfonamide[no description available]low00organonitrogen compound;
organooxygen compound
4-methyl-2-[3-methyl-4-(3-methylphenyl)azo-5-oxo-4H-pyrazol-1-yl]-5-thiazolecarboxylic acid ethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
5'-(4-methylphenyl)-2-spiro[1H-indole-3,2'-3H-1,3,4-thiadiazole]one[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(cyclopentylamino)-1-(4-fluorophenyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-1H-pyrazole-5-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(cyclopentylamino)-1-(3,4-dimethoxyphenyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-1H-pyrazole-5-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
uccf-029[no description available]low00organic heterotricyclic compound;
organooxygen compound
2-(2-furanyl)-2-[(4-methoxyphenyl)methyl-[2-[5-(5-methyl-2-furanyl)-2-tetrazolyl]-1-oxoethyl]amino]-N-(2-oxolanylmethyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[cyclopentyl-[1-oxo-2-(5-thiophen-2-yl-2-tetrazolyl)ethyl]amino]-N-(2-oxolanylmethyl)-2-thiophen-2-ylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(N-[2-(Benzotriazol-1-yl)acetyl]-2,4,6-trimethylanilino)-N-tert-butyl-2-thiophen-3-ylacetamide[no description available]low00organonitrogen compound;
organooxygen compound		anticoronaviral agent
CID 3206295[no description available]low00organonitrogen compound;
organooxygen compound		anticoronaviral agent
N-tert-butyl-2-[(2-chloro-1-oxoethyl)-(2-furanylmethyl)amino]-2-(4-chlorophenyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N'-(1,3-benzodioxol-5-ylmethyl)-N'-[2-(cyclopentylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)butanediamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(3-pyridinyl)amino]-2-(4-chlorophenyl)-N-(2-methoxyethyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-cyclohexyl-2-(4-fluoro-N-[1-oxo-2-(3-thiophenyl)ethyl]anilino)-2-(4-fluorophenyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
1-(2-methyl-2,3-dihydroindol-1-yl)-2-[4-[5-(trifluoromethyl)-1-benzotriazolyl]-1-piperidinyl]ethanone[no description available]low00organonitrogen compound;
organooxygen compound
5-bromo-N-[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]-N-methyl-2-thiophenesulfonamide[no description available]low00organonitrogen compound;
organooxygen compound
N-cyclopentyl-3-[(4-methylphenyl)sulfonylamino]propanamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[(5-bromo-2-thiophenyl)sulfonyl-methylamino]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
3-[(4-methoxyphenyl)sulfonylamino]-N-(phenylmethyl)propanamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(4-methyl-1-oxo-[1]benzothiolo[2,3-d]pyridazin-2-yl)propanoic acid[no description available]low00organonitrogen compound;
organooxygen compound
3-amino-4-(1,3-benzothiazol-2-yl)-N-(3-chloro-2-methylphenyl)-5-phenylimino-2H-thiophene-2-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
6-amino-5-cyano-4-(2-fluorophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyridine-3-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-(5-chloro-2-methoxyphenyl)-2-pyridin-4-yl-4,5-dihydrothiazole-4-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(N-(2-chloro-1-oxoethyl)-3-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
LSM-1924[no description available]low00organic heterotricyclic compound;
organooxygen compound
LSM-16912[no description available]low00organonitrogen compound;
organooxygen compound
N-(4-phenylmethoxyphenyl)-3-[4-(phenylmethyl)-1-piperazinyl]propanamide[no description available]low00organonitrogen compound;
organooxygen compound
3,6-bis[(1H-indol-3-yl)methyl]piperazine-2,5-dione[no description available]low00organonitrogen compound;
organooxygen compound
LSM-22738[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-[1-(cyclopentylamino)-2-methyl-1-oxobutan-2-yl]-N-(thiophen-2-ylmethyl)-2-pyridinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[1-(cyclohexylamino)-2-methyl-1-oxobutan-2-yl]-N-(2-furanylmethyl)-2-pyridinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-N-ethyl-2-(2-methyl-2,3-dihydroindol-1-yl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyrazinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
1-[2-(4-methoxyphenyl)-4-[oxo(1-pyrrolidinyl)methyl]-3-thiazolidinyl]-1-propanone[no description available]low00organonitrogen compound;
organooxygen compound
LSM-26445[no description available]low00organic heterotricyclic compound;
organooxygen compound
2-(N-(2-chloro-1-oxoethyl)-4-fluoroanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(2,3-dioxo-1-indolyl)-N-(2-phenylethyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[5-(phenylmethyl)-2-thiazolyl]-4,5-dihydro-1H-imidazole-2-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
LSM-1925[no description available]low00organic heterotricyclic compound;
organooxygen compound
2-[[(3-amino-4-carbamoyl-5-cyclohexylimino-2H-thiophen-2-yl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester[no description available]low00organonitrogen compound;
organooxygen compound
3-amino-N2-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)imino-2H-thiophene-2,4-dicarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
5'-bromo-2'-spiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3'-1H-indole]one[no description available]low00organonitrogen compound;
organooxygen compound
N-(3,4-dimethylphenyl)-4-oxo-3,10-dihydro-2H-pyrimido[1,2-a]benzimidazole-2-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
LSM-25964[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-(3-oxo-2-benzo[f][1]benzopyranyl)acetamide[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-(5,5-dimethyl-7-oxo-4,6-dihydro-1,3-benzothiazol-2-yl)-2-(2,5-dioxo-1-pyrrolidinyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyridinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
chicoric acid[no description available]low00organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
1-[2-(4-morpholinyl)-2-oxoethyl]-2-pyrido[2,3-b][1,4]thiazinone[no description available]low00organonitrogen compound;
organooxygen compound
aurantiamine[no description available]low00organonitrogen compound;
organooxygen compound
5-aminolevulinic acid hexyl ester[no description available]low00organonitrogen compound;
organooxygen compound
gabalid[no description available]low00organonitrogen compound;
organooxygen compound
tremortin a[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-[3-[(1,3-dimethyl-2,6-dioxo-4-pyrimidinyl)methylamino]-3-oxopropyl]-3-methoxybenzamide[no description available]low00organonitrogen compound;
organooxygen compound
4-chloro-N-[4-[3-(methylthio)anilino]-4-oxobutyl]benzamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(2,6-dichloroanilino)-2-oxoethyl]-N-methyl-4-pyridinecarboxamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[2-(4-chlorophenyl)ethyl]-2-[3-[(2-fluorophenyl)methyl]-2-oxo-1-imidazolidinyl]acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[3-[(2-chloro-4-fluorophenyl)methyl]-2-oxo-1,3-diazinan-1-yl]-N-cyclooctylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
nu 7026[no description available]low00organic heterotricyclic compound;
organooxygen compound
seletracetam[no description available]low00organonitrogen compound;
organooxygen compound
terpendole e[no description available]low00organic heterotricyclic compound;
organooxygen compound
elagolix[no description available]low00organonitrogen compound;
organooxygen compound
citrinadin a[no description available]low00organonitrogen compound;
organooxygen compound
moiramide b[no description available]low00organonitrogen compound;
organooxygen compound
N-[(1,3-dioxo-2-phenyl-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl)methyl]-4-methylbenzenesulfonamide[no description available]low00organonitrogen compound;
organooxygen compound
lc15-0444[no description available]low00organonitrogen compound;
organooxygen compound
2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(4-methoxyphenyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-(4-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(4-methoxyphenyl)acetamide[no description available]low00organonitrogen compound;
organooxygen compound
2-[(2-chloro-1-oxoethyl)-(2,2-dimethoxyethyl)amino]-2-(4-chlorophenyl)-N-cyclohexylacetamide[no description available]low00organonitrogen compound;
organooxygen compound
1-(4-fluorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea[no description available]low00organonitrogen compound;
organooxygen compound
1-(4-methylphenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea[no description available]low00organonitrogen compound;
organooxygen compound
1-(3-chlorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea[no description available]low00organonitrogen compound;
organooxygen compound
N-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]-4-phenyl-1-piperazinecarbothioamide[no description available]low00organonitrogen compound;
organooxygen compound
3-acetamido-N-[4-(4-methylsulfonylphenyl)-2-thiazolyl]-3-phenyl-N-prop-2-enylpropanamide[no description available]low00organonitrogen compound;
organooxygen compound
thallusin[no description available]low00organic heterotricyclic compound;
organooxygen compound
3-[4-[2-(2-fluorophenyl)ethylamino]-3-nitrophenyl]-3-[[2-(1-naphthalenyl)-1-oxoethyl]amino]propanamide[no description available]low00organonitrogen compound;
organooxygen compound
aflatrem[no description available]low00organic heterotricyclic compound;
organooxygen compound
N-[(2-ethoxyphenyl)methyl]-3-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]propanamide[no description available]low00organonitrogen compound;
organooxygen compound
(3S)-3-(2-methylpropyl)-4-oxo-3-phenyldiazetidine-1,2-dicarboxylic acid dimethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
(3S)-3-(4-methoxyphenyl)-4-oxo-3-propan-2-yldiazetidine-1,2-dicarboxylic acid dimethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
(3S)-4-oxo-3-phenyl-3-propan-2-yldiazetidine-1,2-dicarboxylic acid dimethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
(3S)-3-cyclopentyl-4-oxo-3-phenyldiazetidine-1,2-dicarboxylic acid dimethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
(3R)-3-(4-chlorophenyl)-4-oxo-3-propan-2-yldiazetidine-1,2-dicarboxylic acid diethyl ester[no description available]low00organonitrogen compound;
organooxygen compound
LSM-1873[no description available]low00organic heterotricyclic compound;
organooxygen compound
LSM-1834[no description available]low00organic heterotricyclic compound;
organooxygen compound
LSM-1287[no description available]low00organic heterotricyclic compound;
organooxygen compound
LSM-1675[no description available]low00organic heterotricyclic compound;
organooxygen compound
LSM-1312[no description available]low00organic heterotricyclic compound;
organooxygen compound
LSM-1315[no description available]low00organic heterotricyclic compound;
organooxygen compound
gsk 1838705a[no description available]low00organonitrogen compound;
organooxygen compound
3-(4-fluorophenylethylamino)-1-methyl-4-(2-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione[no description available]low00maleimides;
organonitrogen compound;
organooxygen compound
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide[no description available]low00organonitrogen compound;
organooxygen compound
N-[(2S,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide[no description available]low00organonitrogen compound;
organooxygen compound
neosurugatoxin[no description available]low00organonitrogen compound;
organooxygen compound
3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)propoxy)benzoic acid[no description available]low00organonitrogen compound;
organooxygen compound
putreanine[no description available]low00carboxylic acid anion;
N-substituted putrescine;
organonitrogen compound;
organooxygen compound
santacruzamate a[no description available]low00organonitrogen compound;
organooxygen compound
8-epidiosbulbin e acetate[no description available]low00organic heterotricyclic compound;
organooxygen compound
2-[(2-oxo-3-indolyl)amino]-N-(2-phenylethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide[no description available]low00organonitrogen compound;
organooxygen compound
pterine-6-carboxylic acid[no description available]low00organonitrogen compound;
organooxygen compound
conocurvone[no description available]low00organic heterotricyclic compound;
organooxygen compound
phosphocreatinine[no description available]low00organonitrogen compound;
organooxygen compound
carbamic acid[no description available]low00carbon oxoacid;
one-carbon compound;
organonitrogen compound		Escherichia coli metabolite
1,6-bis(cyclohexyloximinocarbonyl)hexane[no description available]low00carbamate ester;
organonitrogen compound
tetranitromethane[no description available]low00organonitrogen compound
methyl 4-mercaptobutyrimidate[no description available]low00organonitrogen compound;
oxoacid derivative
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester[no description available]low00organonitrogen compound;
organosulfur compound
N,N-diethylcarbamodithioic acid (2,2,2-trichloro-1-formamidoethyl) ester[no description available]low00organonitrogen compound;
organosulfur compound
n,n',n''-triacetylfusarinine c[no description available]low00iron coordination entity;
organonitrogen compound
curacin d[no description available]low00heterocyclic compound;
organonitrogen compound;
organosulfur compound
ConditionIndicatedRelationship StrengthStudiesTrials
Abnormalities, Drug-Induced0low10
Absence Seizure0low70
Absence Seizures0low70
Academic Disorder, Developmental0low60
Ache0low10
Acute Confusional Senile Dementia0low60
Acute Onset Vascular Dementia0low10
Adult Learning Disabilities0low60
Adult Learning Disorders0low60
Age-Related Memory Disorders0low60
Aging0low90
Allodynia0low10
Allodynia, Mechanical0low10
Allodynia, Tactile0low10
Allodynia, Thermal0low10
Alloxan Diabetes0low10
Alzheimer Dementia0low60
Alzheimer Disease, Early Onset0low60
Alzheimer Disease, Late Onset0low60
Alzheimer Sclerosis0low60
Alzheimer Syndrome0low60
Alzheimer Type Senile Dementia0low60
Alzheimer-Type Dementia (ATD)0low60
Alzheimer's Disease0low60
Alzheimer's Disease, Focal Onset0low60
Alzheimer's Diseases0low60
Amentia0low20
Amnesia0low90
Amnesia-Memory Loss0low90
Amnesia, Dissociative0low90
Amnesia, Global0low90
Amnesia, Hysterical0low90
Amnesia, Tactile0low90
Amnesia, Temporary0low90
Amnestic State0low90
Anaphylactic Reaction0low10
Anaphylactoid Reaction0low10
Anaphylactoid Shock0low10
Anaphylaxis0low10
Anoxia, Brain0low20
Anoxia, Cerebral0low20
Anoxic Brain Damage0low20
Anoxic Encephalopathy0low20
Anterior Choroidal Artery Infarction0low10
Apoplexy0medium43
Arteriosclerotic Dementia0low10
Arteriosclerotic Encephalopathy, Subcortical0low10
Atonic Absence Seizure0low70
Atonic Absence Seizures0low70
Atonic Seizure0low70
Atonic Seizures0low70
Aura0low30
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome0low10
Autism, Dementia, Ataxia, and Loss of Purposeful Hand Use0low10
Awakening Epilepsy0low30
Benign Psychomotor Epilepsy, Childhood0low10
Binswanger Disease0low10
Binswanger Encephalopathy0low10
Binswanger's Disease0low10
Body Weight0low90
Brain Anoxia0low20
Brain Emboli0low20
Brain Embolism0low20
Brain Embolism and Thrombosis0low20
Brain Hypoxia0low20
Brain Ischemia0low60
Brain Vascular Disorders0low10
Cerebral Anoxia0low20
Cerebral Emboli0low20
Cerebral Embolism0low20
Cerebral Embolism and Thrombosis0low20
Cerebral Hypoxia0low20
Cerebral Infarct0low10
Cerebral Infarction0low10
Cerebral Infarction, Left Hemisphere0low10
Cerebral Infarction, Middle Cerebral Artery0low10
Cerebral Infarction, Right Hemisphere0low10
Cerebral Ischemia0low60
Cerebral Stroke0medium43
Cerebral, Left Hemisphere, Infarction0low10
Cerebral, Right Hemisphere, Infarction0low10
Cerebroatrophic Hyperammonemia0low10
Cerebrovascular Accident0medium43
Cerebrovascular Accident, Acute0medium43
Cerebrovascular Apoplexy0medium43
Cerebrovascular Diseases0low10
Cerebrovascular Disorders0low10
Cerebrovascular Insufficiency0low10
Cerebrovascular Occlusion0low10
Cerebrovascular Stroke0medium43
Chemical Dependence0low20
Childhood Benign Psychomotor Epilepsy0low10
Chronic Progressive Subcortical Encephalopathy0low10
Clonic Seizure0low70
Clonic Seizures0low70
Cognition Disorders0low30
Complex Partial Epilepsy0low10
Complex Partial Seizure0low70
Complex Partial Seizure Disorder0low10
Complex Partial Seizures0low70
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Contact Dermatitis0low10
Convulsion0low70
Convulsion, Non-Epileptic0low70
Convulsions0low70
Convulsive Generalized Seizure Disorder0low10
Convulsive Seizure0low70
Convulsive Seizure Disorder, Generalized0low10
Convulsive Seizures0low70
Cryptogenic Partial Complex Epilepsy0low10
CVA (Cerebrovascular Accident)0medium43
Delayed Effects, Prenatal Exposure0low10
Dementia0low20
Dementia, Alzheimer Type0low60
Dementia, Presenile0low60
Dementia, Primary Senile Degenerative0low60
Dementia, Senile0low60
Dementia, Vascular0low10
Depression0medium21
Depression, Endogenous0low10
Depression, Involutional0medium11
Depression, Neurotic0low10
Depression, Unipolar0low10
Depressive Disorder0low10
Depressive Disorder, Major0medium11
Depressive Syndrome0low10
Dermatitis Venenata0low10
Dermatitis, Contact0low10
Developmental Academic Disability0low60
Developmental Academic Disorder0low60
Developmental Disabilities of Scholastic Skills0low60
Developmental Disorders of Scholastic Skills0low60
Diabetes Mellitus, Experimental0low10
Disease Models, Animal0low100
Disorder, Complex Partial Seizures0low10
Drug Abuse0low20
Drug Addiction0low20
Drug Dependence0low20
Drug Habituation0low20
Drug Use Disorders0low20
Drug Withdrawal Symptoms0low20
Drug-Induced Abnormalities0low10
Early Onset Alzheimer Disease0low60
Eczema, Contact0low10
Embolic Infarction, Middle Cerebral Artery0low10
Embolism0low10
Embolism and Thrombosis, Brain0low20
Embolism, Brain0low20
Embolism, Intracranial0low20
Embolus0low10
Embolus, Middle Cerebral Artery0low10
Encephalopathy, Binswanger0low10
Encephalopathy, Binswanger's0low10
Encephalopathy, Chronic Progressive Subcortical0low10
Encephalopathy, Hypoxic0low20
Encephalopathy, Ischemic0low60
Encephalopathy, Subcortical Arteriosclerotic0low10
Encephalopathy, Subcortical, Chronic Progressive0low10
Epilepsy0low30
Epilepsy, Akinetic0low10
Epilepsy, Atonic0low10
Epilepsy, Benign Psychomotor, Childhood0low10
Epilepsy, Complex Partial0low10
Epilepsy, Cryptogenic0low30
Epilepsy, Cryptogenic, Partial Complex0low10
Epilepsy, Generalized0low10
Epilepsy, Lateral Temporal0low10
Epilepsy, Psychic Equivalent0low10
Epilepsy, Psychomotor0low10
Epilepsy, Symptomatic, Partial Complex0low10
Epilepsy, Temporal Lobe0low10
Epilepsy, Tonic0low10
Epilepsy, Uncinate0low10
Epileptic Seizure0low70
Epileptic Seizures0low70
Experimental Diabetes Mellitus0low10
Eye Diseases0low10
Eye Disorders0low10
Familial Alzheimer Disease (FAD)0low60
Familial Dementia0low20
Fasting Hypoglycemia0low10
Fever, Zika0low10
Focal Onset Alzheimer's Disease0low60
Generalized Absence Seizure0low70
Generalized Absence Seizures0low70
Generalized Convulsive Epilepsy0low10
Generalized Nonconvulsive Epilepsy0low10
Generalized Nonconvulsive Seizure Disorder0low10
Generalized Onset Seizure Disorder0low10
Generalized Seizure Disorder, Convulsive0low10
Generalized Seizure Disorder, Nonconvulsive0low10
Generalized Tonic-Clonic Seizures0low70
Glial Cell Tumors0low10
Glioma0low10
Hyperalgesia0low10
Hyperalgesia, Mechanical0low10
Hyperalgesia, Primary0low10
Hyperalgesia, Secondary0low10
Hyperalgesia, Tactile0low10
Hyperalgesia, Thermal0low10
Hyperalgesic Sensations0low10
Hyperalgia0low10
Hyperalgia, Mechanical0low10
Hyperalgia, Primary0low10
Hyperalgia, Secondary0low10
Hypersensitivity, Contact0low10
Hypoglycemia0low10
Hypoxia, Brain0low20
Hypoxia, Cerebral0low20
Hypoxic Brain Damage0low20
Hypoxic Encephalopathy0low20
Infarction, Cerebral0low10
Infarction, Cerebral, Left Hemisphere0low10
Infarction, Cerebral, Right Hemisphere0low10
Infarction, Left Hemisphere, Cerebral0low10
Infarction, Middle Cerebral Artery0low10
Infarction, Right Hemisphere, Cerebral0low10
Infertility, Male0low10
Injury, Ischemia-Reperfusion0low10
Injury, Reperfusion0low10
Intracranial Embolism0low20
Intracranial Embolism and Thrombosis0low20
Intracranial Vascular Disorders0low10
Ischemia0low10
Ischemia-Reperfusion Injury0low10
Ischemia, Cerebral0low60
Ischemic Encephalopathy0low60
Itching0low10
Jacksonian Seizure0low70
Kidney Papillary Necrosis0low30
Late Effects, Prenatal Exposure0low10
Late Onset Alzheimer Disease0low60
Learning Disabilities0low60
Learning Disorders0low60
Learning Disorders, Adult0low60
Learning Disturbance0low60
Left Hemisphere, Cerebral Infarction0low10
Left Hemisphere, Infarction, Cerebral0low10
Left Middle Cerebral Artery Infarction0low10
Leukoencephalopathy, Subcortical0low10
Major Depressive Disorder0medium11
Malaria, Falciparum0low10
Malignant Glioma0low10
MCA Infarct0low10
MCA Infarction0low10
Mechanical Allodynia0low10
Mechanical Hyperalgesia0low10
Melancholia0low10
Melancholia, Involutional0medium11
Memory Deficits0low60
Memory Disorder, Semantic0low60
Memory Disorder, Spatial0low60
Memory Disorders0low60
Memory Disorders, Age-Related0low60
Memory Loss0low60
Middle Cerebral Artery Circulation Infarction0low10
Middle Cerebral Artery Embolic Infarction0low10
Middle Cerebral Artery Embolus0low10
Middle Cerebral Artery Infarction0low10
Middle Cerebral Artery Occlusion0low10
Middle Cerebral Artery Stroke0low10
Middle Cerebral Artery Syndrome0low10
Middle Cerebral Artery Thrombosis0low10
Middle Cerebral Artery Thrombotic Infarction0low10
Mixed Glioma0low10
Morphine Abuse0low10
Morphine Addiction0low10
Morphine Dependence0low10
Myoclonic Seizure0low70
Myoclonic Seizures0low70
Necrosis0low10
Nerve Pain0low10
Nervous System Diseases0low20
Nervous System Disorders0low20
Neuralgia0low10
Neuralgia, Atypical0low10
Neuralgia, Iliohypogastric Nerve0low10
Neuralgia, Ilioinguinal0low10
Neuralgia, Perineal0low10
Neuralgia, Stump0low10
Neuralgia, Supraorbital0low10
Neuralgia, Vidian0low10
Neuroblastoma0low20
Neurodynia0low10
Neurologic Disorders0low20
Neurological Disorders0low20
Neuropathic Pain0low10
Neurosis, Depressive0low10
Non-Epileptic Seizure0low70
Non-Epileptic Seizures0low70
Nonconvulsive Generalized Seizure Disorder0low10
Nonconvulsive Seizure Disorder, Generalized0low10
Nonepileptic Seizure0low70
Nonepileptic Seizures0low70
Occlusion, Middle Cerebral Artery0low10
Organic Mental Disorders, Substance-Induced0low20
Overinclusion0low30
Pain0low10
Pain, Burning0low10
Pain, Crushing0low10
Pain, Migratory0low10
Pain, Radiating0low10
Pain, Splitting0low10
Paraphrenia, Involutional0medium11
Paroxysmal Nerve Pain0low10
Partial Complex Epilepsy, Cryptogenic0low10
Partial Complex Epilepsy, Symptomatic0low10
Partial Seizure0low70
Partial Seizures0low70
Petit Mal Convulsion0low70
Plasmodium falciparum Malaria0low10
Postabsorptive Hypoglycemia0low10
Posterior Choroidal Artery Infarction0low10
Postprandial Hypoglycemia0low10
Pregnancy0low20
Prenatal Exposure Delayed Effects0low10
Prescription Drug Abuse0low20
Presenile Alzheimer Dementia0low60
Primary Senile Degenerative Dementia0low60
Proteinuria0low10
Pruritis0low10
Pruritus0low10
Psychosis, Involutional0medium11
Reactive Hypoglycemia0low10
Renal Medullary Necrosis0low30
Renal Papillitis, Necrotizing0low30
Reperfusion Damage0low10
Reperfusion Injury0low10
Retention Disorders, Cognitive0low60
Rett Disorder0low10
Rett Syndrome0low10
Rett's Disorder0low10
Rett's Syndrome0low10
Right Hemisphere, Cerebral Infarction0low10
Right Hemisphere, Infarction, Cerebral0low10
Right Middle Cerebral Artery Infarction0low10
Scholastic Skills Development Disorders0low60
Seizure0low70
Seizure Disorder0low30
Seizure Disorder, Complex Partial0low10
Seizure Disorder, Convulsive, Generalized0low10
Seizure Disorder, Generalized0low10
Seizure Disorder, Generalized Nonconvulsive0low10
Seizure Disorder, Generalized Onset0low10
Seizure Disorder, Generalized, Convulsive0low10
Seizure Disorder, Nonconvulsive Generalized0low10
Seizures0low70
Seizures, Auditory0low70
Seizures, Clonic0low70
Seizures, Convulsive0low70
Seizures, Epileptic0low70
Seizures, Focal0low70
Seizures, Generalized0low70
Seizures, Gustatory0low70
Seizures, Motor0low70
Seizures, Olfactory0low70
Seizures, Sensory0low70
Seizures, Somatosensory0low70
Seizures, Tonic0low70
Seizures, Tonic-Clonic0low70
Seizures, Vertiginous0low70
Seizures, Vestibular0low70
Seizures, Visual0low70
Semantic Memory Disorder0low60
Senile Dementia, Acute Confusional0low60
Senile Dementia, Alzheimer Type0low60
Senile Paranoid Dementia0low20
Sensitivity, Contact0low10
Shock, Anaphylactic0low10
Single Seizure0low70
Spatial Memory Disorder0low60
Sterility, Male0low10
Streptozocin Diabetes0low10
Streptozotocin Diabetes0low10
Stroke0medium43
Stroke, Acute0medium43
Stroke, Middle Cerebral Artery0low10
Sub-Fertility, Male0low10
Subcortical Arteriosclerotic Encephalopathy0low10
Subcortical Encephalopathy, Chronic Progressive0low10
Subcortical Infarction0low10
Subcortical Leukoencephalopathy0low10
Subcortical Vascular Dementia0low10
Subfertility, Male0low10
Substance Abuse0low20
Substance Addiction0low20
Substance Dependence0low20
Substance Use0low20
Substance Use Disorders0low20
Substance Withdrawal Syndrome0low20
Substance-Related Disorders0low20
Suffering, Physical0low10
Symptomatic Generalized Epilepsy0low10
Symptomatic Partial Complex Epilepsy0low10
Tactile Allodynia0low10
Testicular Diseases0low20
Thermal Allodynia0low10
Thrombosis, Middle Cerebral Artery0low10
Thrombotic Infarction, Middle Cerebral Artery0low10
Tonic Clonic Seizure0low70
Tonic Seizure0low70
Tonic Seizures0low70
Tonic-Clonic Seizure0low70
Tonic-Clonic Seizures0low70
Unipolar Depression0low10
Vascular Accident, Brain0medium43
Vascular Dementia0low10
Vascular Dementia, Acute Onset0low10
Vascular Diseases, Intracranial0low10
Weight Gain0low30
Withdrawal Symptoms0low20
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (9)

ArticleYear
Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer.
Reproductive toxicology (Elmsford, N.Y.), Volume: 18, Issue: 3		2004
Investigation of testicular toxicity of nefiracetam, a neurotransmission enhancer, in rats.
Toxicology letters, Aug-28, Volume: 143, Issue: 3		2003
Male reproductive toxicity study of nefiracetam in rats.
The Journal of toxicological sciences, Volume: 20, Issue: 3		1995
Reproductive toxicity studies of the new cognition-enhancing agent nefiracetam in rats and rabbits.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in rats.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Thirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Thirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in rats.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Single dose toxicity study of the new cognition-enhancing agent nefiracetam in mice, rats and dogs.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (3)

ArticleYear
Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 31, Issue: 1		2006
Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice.
Journal of neural transmission. General section, Volume: 90, Issue: 2		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (2)

ArticleYear
Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 23, Issue: 1		1993
Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers.
The Journal of pharmacy and pharmacology, Volume: 44, Issue: 9		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (21)

ArticleYear
Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.
Journal of pharmacological sciences, Volume: 117, Issue: 1		2011
CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region.
Journal of neurochemistry, Volume: 106, Issue: 3		2008
Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.
Molecular pharmacology, Volume: 71, Issue: 2		2007
Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam.
Toxicologic pathology, Volume: 33, Issue: 5		2005
Mechanisms of action of cognitive enhancers on neuroreceptors.
Biological & pharmaceutical bulletin, Volume: 27, Issue: 11		2004
Unique mechanism of action of Alzheimer's drugs on brain nicotinic acetylcholine receptors and NMDA receptors.
Life sciences, Dec-05, Volume: 74, Issue: 2-3		2003
Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons.
The Journal of pharmacology and experimental therapeutics, Volume: 307, Issue: 1		2003
Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors.
Annals of the New York Academy of Sciences, Volume: 939		2001
Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
Molecular pharmacology, Volume: 59, Issue: 4		2001
Nefiracetam ameliorates learning deficits in older rabbits and may act via the hippocampus.
Behavioural brain research, Volume: 83, Issue: 1-2		1997
Effects of nefiracetam on amnesia animal models with neuronal dysfunctions.
Behavioural brain research, Volume: 83, Issue: 1-2		1997
Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons.
Neuropharmacology, Volume: 35, Issue: 9-10		1996
Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells.
Brain research, Apr-11, Volume: 642, Issue: 1-2		1994
Oncogenicity studies of the cognition-enhancing agent nefiracetam in mice and rats.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Drug dependence study of the new cognition-enhancing agent nefiracetam in rats.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in rats.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Thirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs.
Arzneimittel-Forschung, Volume: 44, Issue: 2A		1994
Effects of N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats.
Japanese journal of pharmacology, Volume: 50, Issue: 1		1989
Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers.
The Journal of pharmacy and pharmacology, Volume: 44, Issue: 9		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]